



MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

MCL/SE/2024-2025

Date: 12.11.2024

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001(M.H.)

SUBJECT: OUTCOME OF BOARD MEETING HELD ON 12TH NOVEMBER, 2024 PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on today i.e. Tuesday 12th November, 2024 has inter alia considered and approved the following businesses:

- (1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter as well as half year ended on 30th September, 2024 along with Statement of Assets and Liabilities, Cash Flow Statement and Limited Review Report thereon.
- (2) Other routine businesses with the permission of chair.

Further, copy of Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL mode within 24 hours from the conclusion of the Board Meeting.

The aforesaid Un-Audited Standalone and Consolidated Financial Results will be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further the extracts of aforesaid results will be published in Hindi (vernacular) and widely circulated English Newspaper.

The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 4.50 P.M. You are requested to please take on record the same.

Thanking You,

Yours Faithfully,

REGISTERED OFFICE
201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE – 452001
PH:- 0731-4028148, FAX:- 0731-4041435
E mail:- investors@medicaps.com, Web site:- www.medicaps.com



MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

FOR MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Encl.: Un-audited Standalone and Consolidated Financial Results, Statements of Assets and Liabilities & Cash flow along with limited review report for quarter as well as half year ended on 30th September, 2024.

REGISTERED OFFICE

201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE – 452001

PH:- 0731-4028148, FAX:- 0731-4041435

E mail:- investors@medicaps.com, Web site:- www.medicaps.com

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS

412, Arcade Silver 56, 1, New Palasia, Indore - 1

☎ Off. : 2541132, Mobile : 9039080380

E-mail : rawkaassociates@gmail.com, cprawka@gmail.com

LIMITED REVIEW REPORT

Independent Auditor's Review Report on Standalone Un-audited Quarterly and Half year ended Financial Results of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter and half year ended 30th September 2024 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



CONCLUSION

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 12.11.2024


Place: Indore

UDIN: 24429040BKESNN9508

For, Rawka & Associates
(Chartered Accountants)

FRN 021606C




Venus Rawka
(Partner)
M. No. 429040

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	5507.09	0.00	5401.93
XXII	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	0.36	-0.27	1.55	0.09	1.24	3.12
	b) Diluted (Rs.)	0.36	-0.27	1.55	0.09	1.24	3.12
XXIII	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	0.36	-0.27	1.55	0.09	1.24	3.12
	b) Diluted (Rs.)	0.36	-0.27	1.55	0.09	1.24	3.12

DATE: 12.11.2024
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231
UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2024

The standalone Statement of Assets & Liabilities is as under:

		(Amount in Lacs)	
Particulars		As at 30-09-2024	As at 31-03-2024
		unaudited	Audited
I.	Assets		
(1)	Non-Current Assets		
	(a) Property, Plant and Equipment	218.11	226.12
	(b) Capital work-in-progress	0.00	0.00
	(c) Goodwill	0.00	0.00
	(c) Investment Property	0.00	0.00
	(d) Financial Assets		
	(i) Investments	4390.60	4390.58
	(e) Other non-current assets	4.93	4.93
	Sub Total - Non-Current Assets	4613.64	4621.63
(2)	Current assets		
	(a) Inventories		
	(b) Financial Assets	2.94	3.16
	(i) Investments	1294.40	1120.25
	(ii) Trade receivables	403.48	465.04
	(iii) Cash and cash equivalents	7.46	4.54
	(iv) Bank balances other than (iii) above	0.00	0.00
	(c) Other current assets	499.82	594.60
	Sub Total - Current Assets	2208.10	2187.59
	Total Assets	6821.74	6809.22
II.	EQUITY AND LIABILITIES		
	EQUITY		
	(a) Equity Share Capital	1247.00	1247.00
	(b) Other Equity	5507.09	5401.93
	Sub Total - Equity	6754.09	6648.93
	LIABILITIES		
(1)	Non-Current Liabilities		
	(a) Financial Liabilities	0.00	0.00
	(b) Provisions	0.00	0.00
	(c) Deferred tax liabilities (Net)	42.89	42.89
	Sub Total - Non-Current Liabilities	42.89	42.89
(2)	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	0.00	0.00
	(ii) Trade payables	0.00	0.00
	a) total outstanding dues of micro enterprises and small enterprises; and		
	b) total outstanding dues of creditor other than micro enterprises and small enterprises;	6.32	0.50
	(iii) Other financial liabilities (other than those specified in item (b) ,	0.00	0.00
	(b) Other current liabilities	18.44	21.90
	(c) Provisions	0.00	0.00
	(d) Current Tax Liabilities (Net)	0.00	95.00
	Sub Total - Current Liabilities	24.76	117.40
	Total Equity and Liabilities	6821.74	6809.22

DATE:12.11.2024
 PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED


ALOK K GARG
 MANAGING DIRECTOR
 DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
 Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231
UNAUDITED STANDALONE CASH FLOW FOR THE HALF YEAR ENDED 30.09.2024

(Amount in Lacs)

PARTICULARS	Half Year Ended	
	30.09.2024	30.09.2023
A. Cash Flow from Operating Activities		
Net Profit before Tax & Extraordinary Items	11.38	155.00
Adjustment For:		
Depreciation	8.01	8.01
Dividend Income	0.00	0.00
Other Comprehensive Income	93.78	69.93
Profit/(Loss) from Discontinue operation	0.00	0.00
Operating Profit before Working Capital Change	113.17	232.94
Adjustment for Working Capital		
(Increase)/ Decrease in Sundry Debtors	61.56	(143.21)
(Increase)/ Decrease in Inventories	0.22	(4.03)
(Increase)/ Decrease in Loans & Advances	94.77	0.39
Increase/ (Decrease) in Current Liabilities & Prov.	-92.64	3.79
Cash Generated from Working Capital	63.91	(143.06)
Cash generated from Operation	177.08	89.88
Net Income Tax Paid	0.00	0.00
Net cash Flow from Operating Activity	177.08	89.88
B. Cash Flow from Investing Activities		
Sale/(Purchase) of Investments	-174.16	4.37
Sale/(Purchase) of Fixed Assets	0.00	(90.72)
Dividend Received	0.00	0.00
Net Cash used in Investing Activities	-174.16	(86.35)
C. Cash Flow from Financial Activities		
Increase/ (Decrease) in Bank Borrowings	0.00	0.00
Net Cash Used in Financial Activities	0.00	0.00
Net Increase in Cash and Cash Equivalents (A+B+C)	2.92	3.53
Cash & Cash Equivalents at the Beginning of the year	4.54	4.06
Closing of the year	7.46	7.59
Increase in Cash and Cash Equivalents	2.92	3.53

DATE: 12.11.2024
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

LIMITED REVIEW REPORT

Independent Auditor's Review Report on Consolidated Un-audited Quarterly and Half Year ended Financial Results of Medi-Caps Limited (the Parent Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

1. We have reviewed the accompanying Statement of the Consolidated Un-audited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter and Half Year ended September 30, 2024, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the SEBI Listing Regulations'), including relevant circular issued by the SEBI time to time.
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143 of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would



become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly owned subsidiary **Medgel Private Limited**.

CONCLUSION

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI- (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the financial results of Medgel Private Limited (wholly owned subsidiary) which also has been reviewed by us and certified by the management, whose interim consolidated financial results reflect a total income of Rs.858.24 Lakhs, total net Profit after tax of Rs. 31.23 Lakhs and total comprehensive income of Rs. 170.25 Lakhs for the quarter ended September 30, 2024 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of the above matter.

Date: 12.11.2024

Place: Indore

UDIN: 24429040BKESNM9346

For, Rawka & Associates

(Chartered Accountants)

FRN 021606C



Venus Rawka


(Partner)

M. No. 429040

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	11125.54		10851.33
XXII	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	0.25	-0.45	0.09	-0.20	-0.80	-1.80
	b) Diluted (Rs.)	0.25	-0.45	0.09	-0.20	-0.80	-1.80
XXIII	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	0.25	-0.45	0.09	-0.20	-0.80	-1.80
	b) Diluted (Rs.)	0.25	-0.45	0.09	-0.20	-0.80	-1.80

DATE: 12.11.2024
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2024

The Consolidated Statement of Assets & Liabilities is as under:

(Amount in Lacs)

	Particulars	As at 30-09-2024	
		unaudited	Audited
I.	Assets		
	(1) Non-Current Assets		
	(a) Property, Plant and Equipment		2942.66
	(b) Capital work-in-progress	2861.00	0.00
	(c) Goodwill	0.00	0.00
	(c) Investment Property	2814.15	2814.15
	(d) Financial Assets	0.00	0.00
	(i) Investments		
	(e) Other non-current assets	1168.94	931.90
	Sub Total - Non-Current Assets	38.73	38.73
		6882.82	6727.44
	(2) Current assets		
	(a) Inventories		
	(b) Financial Assets	498.19	573.59
	(i) Investments		
	(ii) Trade receivables	3260.44	3014.33
	(iii) Cash and cash equivalents	817.27	1081.72
	(iv) Bank balances other than (iii) above	97.89	32.14
	(c) Other current assets	0.00	0.00
	Sub Total - Current Assets	1335.09	1299.27
	Total Assets	6008.88	6001.05
		12891.70	12728.49
II.	EQUITY AND LIABILITIES		
	EQUITY		
	(a) Equity Share Capital		
	(b) Other Equity	1247.00	1247.00
	Sub Total - Equity	11125.53	10851.33
		12372.53	12098.33
	LIABILITIES		
	(1) Non-Current Liabilities		
	(a) Financial Liabilities		
	(b) Provisions	0.00	0.00
	(c) Deferred tax liabilities (Net)	56.24	61.31
	Sub Total - Non-Current Liabilities	42.89	42.89
		99.13	104.20
	(2) Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	0.00	0.00
	(ii) Trade payables	0.00	0.00
	a) total outstanding dues of micro enterprises and small enterprises; and		
	b) total outstanding dues of creditor other than micro enterprises and small enterprises;		
	(iii) Other financial liabilities (other than those specified in item (b),	172.44	182.53
	(b) Other current liabilities	0.00	0.00
	(c) Provisions	247.60	248.43
	(d) Current Tax Liabilities (Net)	0.00	95.00
	Sub Total - Current Liabilities	420.04	525.96
	Total Equity and Liabilities	12891.70	12728.49

DATE: 12.11.2024

PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED




ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED CONSOLIDATED CASH FLOW FOR THE HALF YEAR ENDED 30.09.2024

PARTICULARS	Amount in Lacs	
	30.09.2024	30.09.2023
A. Cash Flow from Operating Activities		
Net Profit before Tax & Extraordinary Items	-24.42	-99.86
Adjustment For:		
Depreciation	85.13	90.55
Dividend Income	0.00	-0.33
Other Comprehensive Income	298.63	228.25
Loss from discontinue Operation	0.00	0
Operating Profit before Working Capital Change	359.34	218.60
Adjustment for Working Capital		
(Increase)/ Decrease in Sundry Debtors	264.44	-168.48
(Increase)/ Decrease in Inventories	75.40	-19.09
(Increase)/ Decrease in Loans & Advances	-35.82	395.41
Increase/(Decrease) in Current Liabilities & Provisions	-110.98	-160.13
Cash Generated from Working Capital	193.04	47.72
Cash generated from Operation	552.38	266.32
Income Tax for the year	0.00	0
Net cash Flow from Operating Activity	552.38	266.32
B. Cash Flow from Investing Activities		
Sale/(Purchase) of Investments	-483.15	-26.25
Purchase of Fixed Assets	-3.47	-335.62
Dividend Received	0.00	0.33
Net Cash used in Investing Activities	-486.62	-361.54
C. Cash Flow from Financial Activities		
Increase in Short term Bank Borrowings	0.00	0
Proceeds from Long Term Borrowings	0.00	0
Net Cash Used in Financial Activities	0.00	0
Net Increase in Cash and Cash Equivalents (A+B+C)	65.76	-95.22
Cash & Cash Equivalents at the		
Beginning of the year	32.14	111.36
Closing of the year	97.90	16.14
Increase in Cash and Cash Equivalents	65.76	-95.22
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>DATE: 12.11.2024</p> <p>PLACE: INDORE</p> </div> <div style="width: 50%; text-align: right;"> <p>For and on behalf of board of directors of MEDI-CAPS LIMITED</p>  <p>ALOK K GARG MANAGING DIRECTOR DIN: 00274321</p> </div> </div>		

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED CONSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE QUARTER/HALF YEAR ENDED 30.09.2024

S.No.	Segment Revenue	Quarter Ended			Half Year Ended		(Amount in Lacs)
		Sept 30th, 2024	June 30th, 2024	Sept 30th, 2023	Sept 30th, 2024	Sept 30th, 2023	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	March 31st, 2024
1	Segment Revenue						
	Pharma Division	732.10	590.42	397.18	1322.52	1039.04	2050.75
	Real Estate Division	97.52	29.02	213.10	126.54	215.67	731.26
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Net Sale/Income From Operations	829.62	619.44	610.28	1449.06	1254.72	2782.01
2	Segment Results (Profit) (+)/ Loss (-) before tax and Interest						
	Pharma Division	-13.32	-22.48	-181.63	-35.80	-254.86	-607.33
	Real Estate Division	44.54	-33.17	193.24	11.38	155.00	482.73
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total	31.23	-55.65	11.61	-24.42	-99.86	-124.60
	Interest Income	0.00	0.00	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	0.00	0.00	0.00	0.00
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00	0.00	0.00
	Profit Before Tax	31.23	-55.65	11.61	-24.42	-99.86	-124.60
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	6069.96	6058.94	6175.63	6069.96	6175.63	5919.27
	Real Estate Division	6821.74	6728.74	6391.29	6821.74	6391.29	6809.22
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (A)	12891.70	12787.68	12566.92	12891.70	12566.92	12728.49
	Segment Liabilities (B)						
	Pharma Division	451.52	518.86	525.80	451.52	525.80	469.86
	Real Estate Division	67.65	66.52	55.59	67.65	55.59	160.30
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (B)	519.17	585.38	581.38	519.17	581.38	630.16
4	Total Capital Employed (Segment Assets-Segment Liabilities)						
	Pharma Division	5618.44	5540.08	5649.83	5618.44	5649.83	5449.41
	Real Estate Division	6754.09	6662.23	6335.70	6754.09	6335.70	6648.92
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	12372.53	12202.30	11985.53	12372.53	11985.53	12098.33

DATE: 12.11.2024
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED


ALOK K GARG
 MANAGING DIRECTOR
 DIN: 00274321

NOTES:

1. The above standalone and consolidated unaudited financial results for the Quarter and half year ended September 30, 2024, were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on November 12, 2024. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised the necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. This statement has been prepared in accordance with the guidelines issued by the Securities Exchange Board of India (SEBI) and Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists of Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
5. During this quarter the Company has generated revenue of Rs. 96.01 Lacs from sale of shops at Medi-caps Business Park.
6. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.
7. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors

DATE: 12/11/2024
PLACE: INDORE

**For and on behalf of the Board of directors of
MEDI-CAPS LIMITED**



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321